AstraZeneca announced that Brilinta (ticagrelor) is now available. It was approved July 20, 2011, indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS). Brilinta has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with percutaneous coronary intervention (PCI), Brilinta reduced the rate of stent thrombosis.
Brilinta is an oral antiplatelet treatment available in 90mg tablets.
For more information call (800) 236-9933 or visit www.astrazeneca-us.com.